Boston Scientific Shipped Defective Taxus Stents, FDA Warning Letter Says
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific's third warning letter since May faults the firm for shipping defective Taxus drug-eluting stents and not adequately addressing the quality system problem once it was discovered
You may also be interested in...
Boston Scientific Stung With Across-The-Board Corporate Warning Letter
FDA is targeting Boston Scientific with a rare and far-reaching enforcement measure that could prevent some of the firm's investigational products from receiving market approval in the near term
Boston Scientific Stung With Across-The-Board Corporate Warning Letter
FDA is targeting Boston Scientific with a rare and far-reaching enforcement measure that could prevent some of the firm's investigational products from receiving market approval in the near term
Second Warning Letter Directed At Boston Scientific’s Chemotherapy Ports
FDA cites Boston Scientific for quality system regulation violations related to the firm's valved Vaxcel chest ports and catheters in an Aug. 1 1warning letter